Your AI-Trained Oncology Knowledge Connection!
An expert from the Mayo Clinic discusses how findings from the ongoing phase 3 MOUNTAINEER trial may enable access to tucatinib, trastuzumab, and chemotherapy in earlier lines of treatment for patients with HER2-positive metastatic colorectal cancer.
The panel closes by highlighting currently unmet needs in the treatment and management of metastatic colorectal cancer.
Elle Charnisky, a patient with HER2+ metastatic colorectal cancer, and Deanne Griffie, a nurse practitioner, share advice for patients and caregivers living with HER2+ mCRC.
Deanna Griffie, MSN, AGNP-BC, and Tanios Bekaii-Saab, MD, explain how they manage the toxicities of tucatinib in patients with HER2+ mCRC, and how they educate patients on what to expect.
Closing out their review of the metastatic colorectal cancer treatment paradigm, expert panelists consider how the treatment armamentarium will continue to evolve.
Focused discussion on the FRESCO-2 trial, which analyzed use of fruquitinib in the refractory setting of metastatic colorectal cancer.
Shared insight on the potential role for immunotherapeutic agents in the setting of microsatellite stable metastatic colorectal cancer.
Centering discussion on KRASG12C-mutated metastatic colorectal cancer, panelists highlight recent clinical studies of targeted agents in this subset of disease.
John Strickler, MD, details the design and outcomes of the MOUNTAINEER trial investigating the combination treatment of tucatinib with trastuzumab for HER2+ metastatic colorectal cancer.
A panel of expert oncologists discusses advances in the treatment of BRAFV600E metastatic colorectal cancer and also reviews novel targets being investigated in the setting of metastatic colorectal cancer.
Experts offer insights on the appropriate treatment for patients with HER2-positive metastatic colorectal cancer.
Deanna Griffie, MSN, AGNP-BC, shares how common toxicities in patients with HER2+ mCRC being treated with trastuzumab deruxtecan are treated at her clinic.
Dr Tanios Bekaii-Saab describes for which patient groups he would use anti-HER2 therapies as a second-line treatment for HER2+ metastatic colorectal cancer.
Expert panelists review data from the MOUNTAINEER study, which tested tucatinib alone or in combination with trastuzumab in patients with metastatic colorectal cancer.
Patient Elle Charnisky shares her experience with a conventional chemotherapy treatment for her HER2+ metastatic colorectal cancer before transitioning to targeted therapies.
Shared perspective on the use of trastuzumab deruxtecan in HER2+ metastatic colorectal cancer following results from the DESTINY-CRC01 trial.
Dr Bekaii-Saab provides an overview of the first-line treatment options in metastatic colorectal cancer, and the factors that impact treatment decision-making.
Tanios Bekaii-Saab, MD, explains the barriers to molecular testing for patients with metastatic colorectal cancer, and how they can be addressed.
A panel of expert oncologists consider how HER2 expression can positively impact the selection of targeted therapies for patients with metastatic colorectal cancer.
Expert perspectives on the PARADIGM study, which highlighted the role of panitumumab in combination with frontline chemotherapy in patients with left-sided, RAS wild-type metastatic colorectal cancer.
Elle Charnisky describes her experience with molecular testing, and Nurse Practitioner Deanna Griffie details how she explains testing to patients with metastatic colorectal cancer.
Shared insight on the optimal use of circulating tumor DNA and minimal residual disease in the identification and management of metastatic colorectal cancer.
Opening their discussion on metastatic colorectal cancer management, expert panelists reflect on the molecular testing paradigm in the setting of diagnosis and workup.
Dr Tanios Bekaii-Saab explains the rarity of HER2+ metastatic colorectal cancer and how his clinical practice detects HER2 alterations.
Patient Elle Charnisky shares the symptoms that led to her diagnosis of HER2+ metastatic colorectal cancer, and the online resources she used for education after.
Tanios Bekaii-Saab, MD, provides a brief overview of the typical presentation and diagnosis of metastatic colorectal cancer.
Data from the phase 2 DYNAMIC trial show that a circulating tumor DNA–guided approach to adjuvant therapy selection may be feasible for patients with stage II colorectal cancer, but Tanios S. Bekaii-Saab, MD, is skeptical about its readiness for prime time.
Data from the PARADIGM trial that were presented at 2022 ASCO demonstrated that panitumumab plus FOLFOX should be standard of care for patients with left-sided, RAS wild-type colorectal cancer, according to Tanios S. Bekaii-Saab, MD.
Tanios S. Bekaii-Saab, MD, discussed how data from clinical trials examining different targeted strategies in colorectal cancer will transform the way in which patients with this malignancy are seen and treated.
At 2022 ASCO, Tanios S. Bekaii-Saab, MD, talks about how data from the ongoing MOUNTAINEER trial investigating trastuzumab plus tucatinib in HER2-positive metastatic colorectal cancer and other similar trials may impact the standard of care going forward.
